Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
Earnings Call Summary | Vanda Pharmaceuticals(VNDA.US) Q2 2024 Earnings Conference
Cantor Fitzgerald Maintains Overweight on Vanda Pharma, Raises Price Target to $13
Q2 2024 Vanda Pharmaceuticals Inc Earnings Call
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Raises Target Price to $13
Cantor Fitzgerald analyst Charles Duncan maintains $Vanda Pharmaceuticals(VNDA.US)$ with a buy rating, and adjusts the target price from $11 to $13.According to TipRanks data, the analyst has a
Vanda Pharmaceuticals | 10-Q: Q2 2024 Earnings Report